[1] Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am He art J 2004; 147: 536−539. doi: 10.1016/j.ahj.2003.09.018 [2]

Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 2014 15; 59: 1455–1461.

[3]

Smelter D, Hayney M, Sakoulas G, Rose W. Is the success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta? Antimicrob Agents Chemother 2022; 66: e0216621.

[4] Hidalgo-Tenorio C, Gálvez J, Martínez-Marcos FJ, et al. Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aur eus infective endocarditis. BMC Infect Dis 2020; 20: 160. doi: 10.1186/s12879-020-4895-1 [5] Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132: 1435−1486. doi: 10.1161/CIR.0000000000000296 [6]

Ilges D, Krishnan G, Geng E. Persistent methicillin-susceptible bacteremia rapidly cleared with cefazolin and ertapenem combination therapy in a patient with COVID-19. Case Rep Infect Dis 2022; 2022: 6828538.

[7] Smelter D, Hayney M, Sakoulas G, Rose W. Is the success of cefazolin plus ertapenem in methicillin-susceptible staphylococcus aureus bacteremia based on release of interleukin-1 Beta?. Antimicrob Agents Chemother 2022; 66: e0216621. doi: 10.1128/aac.02166-21